BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knieling F, Waldner MJ, Goertz RS, Strobel D. Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma. BMJ Case Rep. 2012;2012. [PMID: 23257272 DOI: 10.1136/bcr-2012-007576] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Knieling F, Cesnjevar R, Regensburger AP, Wagner AL, Purbojo A, Dittrich S, Münch F, Neubert A, Woelfle J, Jüngert J, Rüffer A. Transfontanellar Contrast-enhanced US for Intraoperative Imaging of Cerebral Perfusion during Neonatal Arterial Switch Operation. Radiology 2022;:212044. [PMID: 35380495 DOI: 10.1148/radiol.212044] [Reference Citation Analysis]
2 Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372 [PMID: 31148907 DOI: 10.3748/wjg.v25.i19.2365] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
3 Liu KY, Wang LT, Hsu SH. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E8. [PMID: 29301348 DOI: 10.3390/cancers10010008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
4 Lo GM, Al Zahrani H, Jang HJ, Menezes R, Hudson J, Burns P, Mcnamara MG, Kandel S, Khalili K, Knox J, Rogalla P, Kim TK. Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in Medicine & Biology 2016;42:1303-11. [DOI: 10.1016/j.ultrasmedbio.2016.01.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
5 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
6 Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070 [PMID: 26576091 DOI: 10.3748/wjg.v21.i42.12059] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
7 Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer 2020;20:1001. [PMID: 33059615 DOI: 10.1186/s12885-020-07471-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Murray M, Gillani TB, Rawling T, Nair PC. Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib. AAPS J 2019;21:107. [PMID: 31637538 DOI: 10.1208/s12248-019-0374-2] [Reference Citation Analysis]